ABOUT IPGA
Indian Pharmacy Graduates’ Association was established in the Year 1973. The association is registered as a society under the societies registration act, 1860. The association is affiliated to Indian Pharmaceutical Congress Association (IPCA), the Federal Body of the five associations namely IPGA, IPA, IHPA, APTI and AIDCOC. IPGA is a national level Association of Indian Pharmacy Graduates. It has been working from the last 30 years for the upliftment of professionals of Pharmacy. Present IPGA has more then 6000 Life members in 19 state branches all across the country. I PGA has been constantly engaged in conducting Workshops, Annual Conferences, Seminars and other activities to update the knowledge and skills of pharmacy professionals. It also publish quarterly news letters in the name of IPGA TODAY, which covers the various activities performed by the state branches and other article on recent advancement and pharmaceutical sciences. IPGA is a charitable professional organization and is exempted from contributions under the section 80G of Income Tax Act, 1961
The U.S. Food and Drug Administration (FDA) has approved Bayer AG’s new low dose levonorgestrel-releasing intrauterine system (LNG-IUS) which will be marketed in the US under the brand name Kyleena™. Kyleena releases the lowest daily dose of the hormone levonorgestrel in an intrauterine system for up to five years of effective protection against pregnancy, using the smallest T-shaped body in an IUS available today. Long-acting contraception is one of the most effective methods of birth control as it does not require user interventions such as daily dosing or monthly re-fills. An LNG-IUS can be removed at any time and offers rapid return to a woman’s natural level of fertility after removal.
[adsense:336x280:8701650588]

Shire traces its history back to 1986, when a small team of entrepreneurs sought out a solution to address on a number of unmet medical needs. Within its first two years of operation, the company had launched a range of supplemental calcium products for patients seeking to treat or prevent osteoporosis. Soon thereafter, innovative drug development programs were under way on behalf of patients facing such challenging conditions as Alzheimer's disease and end-stage renal failure.


